The association of the <i>BRAF</i>^V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer

This meta-analysis demonstrates that the BRAF(V600E) mutation is closely related to the high-risk clinicopathological factors and poorer outcome of PTC. The results obtained here suggest that the BRAF(V600E) mutation should be considered as a poor prognostic marker in PTC and may lead to better management for individual patients.